Artigos de revistas sobre o tema "Equity lines"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Equity lines".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
ANNAOUI, Ilias, e Pascal BARNETO. "The Determinants of Equity Lines Financing: An International Study". Bankers, Markets & Investors 171, n.º 3 (22 de dezembro de 2022): 43–50. http://dx.doi.org/10.54695/bmi.171.8461.
Texto completo da fonteEbens, Allen J., Leanne Berry, Yung-Hsiang Chen, Gauri Deshmukh, Jake Drummond, Changchun Du, Michael Eby et al. "A Selective PIM Kinase Inhibitor Is Highly Active In Multiple Myeloma: The Biology of Single Agent and PI3K/AKT/mTOR Combination Activity". Blood 116, n.º 21 (19 de novembro de 2010): 3001. http://dx.doi.org/10.1182/blood.v116.21.3001.3001.
Texto completo da fonteAnnaoui, Ilias, e Pascal Barneto. "Mécanismes de gouvernance et financement par Equity lines". Management & Avenir N° 135, n.º 3 (6 de junho de 2023): 37–60. http://dx.doi.org/10.3917/mav.135.0037.
Texto completo da fonteNgo, Anh, Oscar Varela e Xie Feixue. "The effects of lines of credit on market timing and the underpricing of seasoned equity offerings". Review of Accounting and Finance 18, n.º 1 (11 de fevereiro de 2019): 157–75. http://dx.doi.org/10.1108/raf-09-2016-0153.
Texto completo da fonteThomenius, Michael J., Jennifer Totman, Kat Cosmopoulos, Dorothy Brach, Lei Ci, Neil Farrow, Jesse J. Smith et al. "Identification of a First-in-Class SETD2 Inhibitor That Shows Potent and Selective Anti-Proliferative Activity in t(4;14) Multiple Myeloma: T(4;14) Multiple Myeloma Cells Are Dependent on Both H3K36 Di and Tri-Methylation". Blood 132, Supplement 1 (29 de novembro de 2018): 3207. http://dx.doi.org/10.1182/blood-2018-99-110803.
Texto completo da fonteMunugalavadla, Veerendra, Leanne Berry, Yung-Hsiang Chen, Gauri Deshmukh, Jake Drummond, Changchun Du, Michael Eby et al. "A Selective PIM Kinase Inhibitor Is Highly Active In Multiple Myeloma: Mechanism of Action and Signal Transduction Studies". Blood 116, n.º 21 (19 de novembro de 2010): 4084. http://dx.doi.org/10.1182/blood.v116.21.4084.4084.
Texto completo da fonteDornan, David, Bart Burington, Peng Yue, Xiaoyan Shi, Ranjana Advani, Nancy Yu, Jeffrey T. Lau et al. "CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma." Blood 114, n.º 22 (20 de novembro de 2009): 2721. http://dx.doi.org/10.1182/blood.v114.22.2721.2721.
Texto completo da fonteSALANDRO, DAN, e WILLIAM B. HARRISON. "Determinants of the Demand for Home Equity Credit Lines". Journal of Consumer Affairs 31, n.º 2 (dezembro de 1997): 326–45. http://dx.doi.org/10.1111/j.1745-6606.1997.tb00394.x.
Texto completo da fonteLiu, Yang, e J. Jimmy Yang. "Private debt, unused credit lines, and seasoned equity offerings". Quarterly Review of Economics and Finance 51, n.º 4 (novembro de 2011): 376–88. http://dx.doi.org/10.1016/j.qref.2011.07.006.
Texto completo da fonteNadelson, Louis S., Rachelle G. Miller, Helen Hu, Na Mi Bang e Brandy Walthall. "Is Equity on Their Mind? Documenting Teachers’ Education Equity Mindset". World Journal of Education 9, n.º 5 (17 de outubro de 2019): 26. http://dx.doi.org/10.5430/wje.v9n5p26.
Texto completo da fonteEastman, Stephen, Christopher Shelton, Ira Gupta, Julie Krueger, Christina Blackwell e Paul M. Bojczuk. "Synergistic Activity of Belantamab Mafodotin (anti-BCMA immuno-conjugate) with PF-03084014 (gamma-secretase inhibitor) in Bcma-Expressing Cancer Cell Lines". Blood 134, Supplement_1 (13 de novembro de 2019): 4401. http://dx.doi.org/10.1182/blood-2019-123705.
Texto completo da fonteUlanet, Danielle, Victor Chubukov, John Coco, Gabrielle McDonald, Mya Steadman, Rohini Narayanaswamy, Sebastien Ronseaux et al. "Hematologic Malignancies Exhibit Selective Vulnerability to Inhibition of De Novo Pyrimidine Biosynthesis By AG-636, a Novel Inhibitor of Dihydroorotate Dehydrogenase in Phase 1 Clinical Trials". Blood 134, Supplement_1 (13 de novembro de 2019): 1570. http://dx.doi.org/10.1182/blood-2019-123471.
Texto completo da fonteSampath, Deepak, Elizabeth Punnoose, Erwin R. Boghaert, Lisa Belmont, Jun Chen, Franklin Peale, Nguyen Tan et al. "Expression of Bcl-2 Pro-Survival Family Proteins Predicts Pharmacological Responses to ABT-199, a Novel and Selective Bcl-2 Antagonist, in Multiple Myeloma Models". Blood 120, n.º 21 (16 de novembro de 2012): 5028. http://dx.doi.org/10.1182/blood.v120.21.5028.5028.
Texto completo da fonteErickson-Miller, Connie L., Jennifer Kirchner, Kodandaram Pillarisetti, Lone Ottesen, Yasser Mostafa Kamel, Yuan Liu, Anne-Marie Martin e Conrad Messam. "Eltrombopag Decreases Proliferation of Ovarian, Lung and Breast Tumor Cell Lines." Blood 114, n.º 22 (20 de novembro de 2009): 2409. http://dx.doi.org/10.1182/blood.v114.22.2409.2409.
Texto completo da fontePramanik, Anik, Pan Xu e Yifan Xu. "Equity Promotion in Public Transportation". Proceedings of the AAAI Conference on Artificial Intelligence 37, n.º 10 (26 de junho de 2023): 11890–98. http://dx.doi.org/10.1609/aaai.v37i10.26403.
Texto completo da fonteMaira Muniz Almeida, Wanda, e Eliane Guaraldo. "Urban Green Equity". Life Style 8, n.º 2 (2 de junho de 2022): 64–74. http://dx.doi.org/10.19141/2237-3756.lifestyle.v8.n2.p64-74.
Texto completo da fontePrabhu, Varun V., Rohinton S. Tarapore, Mathew J. Garnett, Ultan McDermott, Cyril H. Benes, Jessica M. Wagner, Wafik S. El-Deiry, Martin Stogniew, Wolfgang Oster e Joshua E. Allen. "Potent Anti-Leukemic Effects of Small Molecule ONC212, a Member of the Imipridone Class of Anti-Cancer Compounds". Blood 128, n.º 22 (2 de dezembro de 2016): 5133. http://dx.doi.org/10.1182/blood.v128.22.5133.5133.
Texto completo da fonteThakurta, Anjan, Anita K. Gandhi, Michelle Waldman, Chad C. Bjorklund, Suzanne Lentzsch, Stephen A. Schey, Yolanda Calle et al. "Absence Of Mutation In Cereblon (CRBN) and DNA Damage Binding Protein 1 (DDB1) Genes In Myeloma Cells and Patients and Its Clinical Significance". Blood 122, n.º 21 (15 de novembro de 2013): 3139. http://dx.doi.org/10.1182/blood.v122.21.3139.3139.
Texto completo da fonteArora, Shilpi, Kaylyn Williamson, Shruti Apte, Srividya Balachander, Jennifer Busby, Charlie Hatton, Barbara Bryant e Patrick Trojer. "EZH2 Inhibitors Are Broadly Efficacious in Multiple Myeloma As Single Agent and in Combination with Standard of Care Therapeutics". Blood 128, n.º 22 (2 de dezembro de 2016): 5672. http://dx.doi.org/10.1182/blood.v128.22.5672.5672.
Texto completo da fonteWang, Xiaomin, e Wenxin Zhang. "Efficiency and Spatial Equity Impacts of High-Speed Rail on the Central Plains Economic Region of China". Sustainability 11, n.º 9 (5 de maio de 2019): 2583. http://dx.doi.org/10.3390/su11092583.
Texto completo da fonteAhsan, Aarif, Ann Polonskaia, Chih-Chao Hsu, Chad C. Bjorklund, Maria Ortiz Estevez, Fadi Towfic, Nizar J. Bahlis et al. "Super-Enhancer Driven Regulation of CKS1B in Multiple Myeloma: Implications in Mediating Response to BET Inhibitor and Celmod Agent Combination". Blood 138, Supplement 1 (5 de novembro de 2021): 2658. http://dx.doi.org/10.1182/blood-2021-150641.
Texto completo da fonteChen, Janice, Christopher L. Brooks, Peter McDonald, Jonathan D. Schwartz, Rebecca S. Schneider, Keiichi Sakakibara, Naoya Saito, Takuji Sato, Takumi Kawabe e Eric K. Rowinsky. "SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with Broad and Potent Anti-Cancer Activity". Blood 126, n.º 23 (3 de dezembro de 2015): 4433. http://dx.doi.org/10.1182/blood.v126.23.4433.4433.
Texto completo da fonteLiu, Yang. "The Sources of Debt Matter Too". Journal of Financial and Quantitative Analysis 41, n.º 2 (junho de 2006): 295–316. http://dx.doi.org/10.1017/s0022109000002076.
Texto completo da fontePeng, Mao Yu, Yasmin Abaza, Martina Mcdermott, Monica Mead, Dennis J. Slamon e Sarah Larson. "Activity of Carfilzomib (CFZ) in Acute Myeloid Leukemia (AML) As a Single Agent and in Novel Combinations". Blood 136, Supplement 1 (5 de novembro de 2020): 6–7. http://dx.doi.org/10.1182/blood-2020-141459.
Texto completo da fonteZhang, Yue, Julie Parmentier, Zhongwu Lai, Greg O'Connor, Melissa Passino, Francoise Powell, Erik Devereaux e Kate Byth. "Spleen Tyrosine Kinase Inhibitor Fostamatinib Blocks B Cell Receptor Signaling and Reduces Viability of BCR Subtype Diffuse Large B Cell Lymphoma". Blood 120, n.º 21 (16 de novembro de 2012): 3720. http://dx.doi.org/10.1182/blood.v120.21.3720.3720.
Texto completo da fonteFernández, Leonor, e Peter Shorett. "Lessons in Equity From the Front Lines of COVID-19 Vaccination". JAMA Health Forum 2, n.º 4 (7 de abril de 2021): e210612. http://dx.doi.org/10.1001/jamahealthforum.2021.0612.
Texto completo da fonteTurner, PG. "Fault Lines In Equity Edited by Jamie Glister and Pauline Ridge". Oxford University Commonwealth Law Journal 12, n.º 2 (27 de março de 2012): 393–97. http://dx.doi.org/10.1080/14729342.2012.11421351.
Texto completo da fonteGandhi, Anita K., Herve Avet-Loiseau, Michelle Waldman, Anjan Thakurta, Sharon L. Aukerman, Gengxin Chen, Derek Mendy et al. "Detection and Quantification of Cereblon Protein and mRNA in Multiple Myeloma Cell Lines and Primary CD138+multiple Myeloma Cells". Blood 120, n.º 21 (16 de novembro de 2012): 4043. http://dx.doi.org/10.1182/blood.v120.21.4043.4043.
Texto completo da fonteLopez-Girona, Antonia, Courtney G. Havens, Gang Lu, Emily Rychak, Derek Mendy, Bonny Gaffney, Christine Surka et al. "CC-92480 Is a Novel Cereblon E3 Ligase Modulator with Enhanced Tumoricidal and Immunomodulatory Activity Against Sensitive and Resistant Multiple Myeloma Cells". Blood 134, Supplement_1 (13 de novembro de 2019): 1812. http://dx.doi.org/10.1182/blood-2019-124338.
Texto completo da fonteLyons, Torrey, e Dong-ah Choi. "Transit Economic Equity Index: Developing a Comprehensive Measure of Transit Service Equity". Transportation Research Record: Journal of the Transportation Research Board 2675, n.º 3 (7 de janeiro de 2021): 288–300. http://dx.doi.org/10.1177/0361198120970529.
Texto completo da fonteRivera, Victor M., Justin R. Pritchard, Francois Gonzalvez, Theresa Baker, Joseph M. Gozgit e Graeme Hodgson. "Comparative TKI Profiling Analyses to Explore Potential Mechanisms of Ponatinib-Associated Arterial Thrombotic Events". Blood 124, n.º 21 (6 de dezembro de 2014): 1783. http://dx.doi.org/10.1182/blood.v124.21.1783.1783.
Texto completo da fonteLi, Lingna, Wenyong Tong, Megan Lau, Katherine Fells, Tong Zhu, Yingqing Sun, Ernest Kovacs et al. "Preclinical Development of an Anti-CD38 Antibody-Drug Conjugate for Treatment of Hematological Malignancies". Blood 134, Supplement_1 (13 de novembro de 2019): 5621. http://dx.doi.org/10.1182/blood-2019-132062.
Texto completo da fonteWang, Beatrice T., Thomas J. Matthew, Ling Wang, Tasnim Kothambawala, Susan E. Calhoun, Eric W. Humke, Angus M. Sinclair e Bruce A. Keyt. "The Anti-Tumor Activity of Igm-8444, an Agonistic Death Receptor 5 (DR5) IgM Antibody, Is Sensitized in Combination with Chemotherapy and Bcl-2 Inhibitors in NHL and AML". Blood 136, Supplement 1 (5 de novembro de 2020): 43–44. http://dx.doi.org/10.1182/blood-2020-141449.
Texto completo da fonteBates, Jamie, Saritha Kusam, Stacey Tannheimer, Astrid Clarke, Thomas Kenney, David Breckenridge e Daniel Tumas. "Combination of the BET Inhibitor GS-5829 and a BCL2 Inhibitor Resulted in Broader Activity in DLBCL and MCL Cell Lines". Blood 128, n.º 22 (2 de dezembro de 2016): 5104. http://dx.doi.org/10.1182/blood.v128.22.5104.5104.
Texto completo da fonteCojocari, Dan, Sha Jin, Julie J. Purkal, Relja Popovic, Nari N. Talaty, Yu Xiao, Larry R. Solomon, Erwin Boghaert, Joel D. Leverson e Darren C. Phillips. "5-Azacytidine Induces NOXA and PUMA Expression to Prime AML Cells for Venetoclax-Mediated Apoptosis". Blood 132, Supplement 1 (29 de novembro de 2018): 2644. http://dx.doi.org/10.1182/blood-2018-99-111985.
Texto completo da fontePinho, Pedro, Helen Kylefjord, Vilma Rraklli, Christina Rydergård, Biljana Rizoska, Anders Eneroth, Johan Bylund et al. "Protides of 5-Fluorotroxacitabine Display Potent Anti-Proliferative Properties and Circumvent Deoxycytidine Kinase-Mediated Resistance Associated with Cytotoxic Cytidine Analogues; A Novel Approach for Acute Myeloid Leukemia". Blood 132, Supplement 1 (29 de novembro de 2018): 3497. http://dx.doi.org/10.1182/blood-2018-99-114440.
Texto completo da fonteKlatt, Martin G., Zhiyuan Yang, Jianying Liu, Tatyana Korontsvit, Sung Soo Mun, Leila Peraro, Thomas J. Gardner et al. "A TCR Mimic Antibody-Directed CAR T Cell Specific for Intracellular NDC80 Is Broadly Cancer Reactive and Displays High Activity Against Hematological Malignancies". Blood 136, Supplement 1 (5 de novembro de 2020): 20–21. http://dx.doi.org/10.1182/blood-2020-140179.
Texto completo da fonteTotman, Jennifer, Dorothy Brach, Vinny Motwani, Selene Howe, Emily Deutschman, John Lampe, Thomas V. Riera et al. "Pharmacologic Inhibition of the Histone Methyltransferase SETD2 with EZM0414 As a Novel Therapeutic Strategy in Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma". Blood 138, Supplement 1 (5 de novembro de 2021): 1142. http://dx.doi.org/10.1182/blood-2021-151147.
Texto completo da fonteCheung, Kam, Gloria Juan, William Wayne, Kelly Hanestad, Kathleen Keegan, Justin Huard, Patricia McElroy et al. "AMG 900, a Potent and Highly Selective Aurora Kinase Inhibitor Shows Promising Preclinical Activity Against Acute Myeloid Leukemia Cell Lines In Vitro and In Vivo". Blood 122, n.º 21 (15 de novembro de 2013): 3823. http://dx.doi.org/10.1182/blood.v122.21.3823.3823.
Texto completo da fonteChen, Jun, Sha Jin, Paul Tapang, Stephen K. Tahir, Morey Smith, John Xue, Haichao Zhang et al. "CDK9 Inhibition Reverses Resistance to ABT-199 (GDC-0199) By Down-Regulating MCL-1". Blood 124, n.º 21 (6 de dezembro de 2014): 2161. http://dx.doi.org/10.1182/blood.v124.21.2161.2161.
Texto completo da fontePenebre, Elayne, Kristy G. Kuplast, Christina R. Majer, L. Danielle Johnston, Nathalie Rioux, Michael Munchhof, Lei Jin et al. "Identification of a First-in-Class PRMT5 Inhibitor with Potent in Vitro and in Vivo Activity in Preclinical Models of Mantle Cell Lymphoma". Blood 124, n.º 21 (6 de dezembro de 2014): 438. http://dx.doi.org/10.1182/blood.v124.21.438.438.
Texto completo da fonteWeyland, Kurt. "“Growth With Equity” in Chile's New Democracy?" Latin American Research Review 32, n.º 1 (1997): 37–68. http://dx.doi.org/10.1017/s0023879100037651.
Texto completo da fonteRychak, Emily, Derek Mendy, Karen Miller, Jim Leisten, Rama Krishna Narla, Heather K. Raymon, Rajesh Chopra e Antonia Lopez-Girona. "The Novel mTOR Kinase Inhibitor CC-223 Demonstrates Significant Activity In In Vitro Models Of Multiple Myeloma (MM), Both As a Single Agent and In Combination With The Approved Agents, Dexamethasone, Lenalidomide and Pomalidomide". Blood 122, n.º 21 (15 de novembro de 2013): 3160. http://dx.doi.org/10.1182/blood.v122.21.3160.3160.
Texto completo da fonteMcElligott, David L., Edward Kesicki, Kannan Karukarichi, Hyeseok Shim, Rui Wang, Albert S. Yu, Parisa Zolfaghari et al. "Development of Inhibitors of PIP4K2 As a Treatment for Patients with Hematologic Malignancies". Blood 132, Supplement 1 (29 de novembro de 2018): 213. http://dx.doi.org/10.1182/blood-2018-99-118355.
Texto completo da fonteCsibi, Fred, Nan Ji, Bin Yang, Karen Yuan, Michele Mayo, Haojing Rong, Scott Rusin et al. "Small Molecule-Induced, Selective STAT3 Degradation Leads to Anti-Tumor Activity in STAT3-Dependent Heme Malignancies". Blood 134, Supplement_1 (13 de novembro de 2019): 3803. http://dx.doi.org/10.1182/blood-2019-128981.
Texto completo da fonteDing, Bei Bei, John Dixon Gray, Irina Krapf, Yanliang Zhang, Nan Zhang, Qingdong Mark Deng, Angel Wei et al. "Development of a Genetically-Engineered Allogeneic Anti-CD38 T Cell Therapy Utilizing a Novel Antigen Receptor Structure". Blood 134, Supplement_1 (13 de novembro de 2019): 4444. http://dx.doi.org/10.1182/blood-2019-131586.
Texto completo da fonteFiore, Christopher, Michael R. McKeown, Emily Lee, Matthew L. Eaton e Christian C. Fritz. "SY1425 (tamibarotene) Induces Profound Transcriptional Changes in AML Tumors with High Retinoic Acid Receptor Alpha". Blood 128, n.º 22 (2 de dezembro de 2016): 1523. http://dx.doi.org/10.1182/blood.v128.22.1523.1523.
Texto completo da fonteLowe, Eric, Andrea R. Fan, Jing Jiang, Henry W. B. Johnson, Christopher J. Kirk, Dustin McMinn, Tony Muchamuel, Yu Qian e Brian B. Tuch. "Blocking Protein Secretion with Novel Small Molecule Inhibitors of Sec61 Represents a Potential Treatment Strategy Against Hematologic Malignancies". Blood 134, Supplement_1 (13 de novembro de 2019): 408. http://dx.doi.org/10.1182/blood-2019-123782.
Texto completo da fonteYang, Jun, Andong Guo, Xueming Li e Tai Huang. "Study of the Impact of a High-Speed Railway Opening on China’s Accessibility Pattern and Spatial Equality". Sustainability 10, n.º 8 (19 de agosto de 2018): 2943. http://dx.doi.org/10.3390/su10082943.
Texto completo da fonteAryal, Neeraj K., Anjana Sundarrajan, Scott Boiko, David Jenkins, Huayang Liu, Miika Ahdesmaki, Aurelie Bornot et al. "Elongator Complex Regulates MCL1 Dependency Via IRE1-XBP1 Axis of the ER Stress Response Pathway in Multiple Myeloma". Blood 138, Supplement 1 (5 de novembro de 2021): 2275. http://dx.doi.org/10.1182/blood-2021-151194.
Texto completo da fonte